owing to a higher rate of readmission. Limitations to our study include limited information regarding long-term follow-up, cost, and stratification based on institution type or hospital volume. There are also constraints inherent in the database we used such as potential variability in the interpretation of patient data by those who compile the database. These findings emphasize that proper discharge planning and medical support after discharge are of utmost importance. 
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Frequency of Misinterpretation of Inconclusive Noninferiority Trials: The Case of the Laparoscopic vs Open Resection for Rectal Cancer Trials
Noninferiority clinical trials are designed to determine whether an intervention is not worse than a comparator by a prespecified difference, known as the noninferiority margin (ΔNI). These trials are useful when comparing standard therapies with novel treatments that may be easier to use, are less costly, or have fewer adverse effects.
1 The number of noninferiority trials is increasing; however, particularly compared with superiority trials, the interpretation of noninferiority trials is not straightforward. Superiority trials can be classified as positive or negative based on whether the null hypothesis can be rejected (ie, P < .05). In contrast, noninferiority trials can be interpreted as noninferior, inconclusive, or not noninferior according to the location Error bars indicate 95% CIs. A, Shown are examples of noninferiority (NI) trial results and their interpretation according to the CONSORT recommendations. In example 1, if the 95% CI lies wholly to the left of zero, the new intervention is superior. In examples 2 and 3, if the 95% CI lies to the left of ΔNI and includes zero, the new treatment is noninferior but not shown to be superior. In example 4, if the 95% CI lies wholly to the left of ΔNI and wholly to the right of zero, the new treatment is noninferior in the sense already defined, but it is also inferior in the sense that a null treatment difference is excluded. In examples 5 and 6, if the 95% CI includes ΔNI and zero, the difference is not significant, but the result regarding noninferiority is inconclusive. In example 7, if the 95% CI includes ΔNI and is wholly to the right of zero, the difference is statistically significant, but the result is inconclusive regarding possible inferiority. Last, in example 8,ifthe95%CIiswhollyaboveΔNI,thenewtreatmentisnotnoninferior(looking-glass opposite of noninferior as inferior is also used to refer to the opposite to superior). The vertical dotted lines indicate the noninferiority margin (ΔNI). B, Results of the ACOSOG Z6051 and ALaCaRT trials are presented as risk differences and 95% CIs with their respective ΔNI. The ACOSOG Z6051 noninferiority margin is risk difference 6.0 (Δ2); the ALaCaRT noninferiority margin is risk difference 8.0 (Δ1). As seen, the results of the ACOSOG Z6051 trial correspond to example 6, and the results of the ALaCaRT trial correspond to example 7. The vertical dotted lines indicate the noninferiority margin from the ACOSOG Z6051 trial (Δ1) and the ALaCaRT trial (Δ2).
of the 95% CIs in relation to the prespecified margin ( Figure) . Inconclusive and not noninferior results are often both presented as "negative" results (eg, failure to meet noninferiority criteria). This can lead readers to erroneously interpret an inconclusive trial as showing evidence that the novel treatment is worse, while in reality the findings are indeterminate and further research is required to determine noninferiority. ]) evaluating the surgical treatment of rectal cancer that had inconclusive results regarding the noninferiority of laparoscopy in terms of quality of surgical resection ( Figure) . Both trials used correct yet ambiguous wording (ie, failed to meet the criteria for noninferiority) to report their findings.
2,3 Publication of these 2 randomized clinical trials (RCTs) reignited concerns regarding the oncologic safety of the laparoscopic approach for rectal cancer. 2, 3 To evaluate the frequency of misinterpretation of these inconclusive trials, we examined publications citing the ACOSOG Z6051 and ALaCaRT trials and determined whether interpretations were concordant with the findings of the primary studies. Discussion | This cross-sectional analysis of 71 articles discussing the ACOSOG Z6051 and ALaCaRT trials 2,3 demonstrates that noninferiority trials with inconclusive results are often misinterpreted or described using correct yet ambiguous language that may obscure the true trial results. Most previous analyses of noninferiority trials have focused on quality and completeness of reporting of design variables and results.
Limitations. This study has some limitations. These include the use of Scopus, which may not have accurately identified all articles citing the 2 trials studied. Moreover, our findings might not be generalizable to other noninferiority trials.
Conclusions | Our analysis is the first that we know of to explore the interpretation of inconclusive noninferiority trials among knowledge users. Appropriate interpretation of these studies is important because decisions about the use of new therapies increasingly rely on data from noninferiority trials. Explicit statements in publications of noninferiority trials when the findings are inconclusive would aid interpretation and avoid erroneous conclusions that novel treatments are inferior. 
